---
title: "BTIG maintains Buy rating on ArriVent BioPharma, $29 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301141659.md"
description: "BTIG maintains a Buy rating on ArriVent BioPharma with a $29 price target, implying 92.2% upside from the Oct 6 close of $15.09. The firm cites ArriVent's strong cash position of $373 million, supporting operations through 2028. Key pipeline assets include ARR-217, an ADC entering Phase 1 trials, and firmonertinib, expected for US approval by 2029. These factors justify the positive outlook."
datetime: "2026-10-07T12:03:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301141659.md)
  - [en](https://longbridge.com/en/news/301141659.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301141659.md)
generator: "portal-rs"
---

# BTIG maintains Buy rating on ArriVent BioPharma, $29 price target

BTIG maintained their Buy rating on ArriVent BioPharma's stock with a price target of $29.00.

The price target implies an upside of 92.2% from the Oct 6 close of $15.09.

**Key takeaways from the analyst note**

**Strong Cash Position and Long Runway**: ArriVent BioPharma has a robust cash position of $373 million, providing a runway into 2028. This financial stability allows the company to strategically advance its product pipeline, including the promising dual MUC16/NaPi2B antibody-drug conjugate (ADC) ARR-217, which is set to initiate Phase 1 trials soon.

**Promising Pipeline and Future Potential**: The company's lead candidate, firmonertinib, is projected to receive regulatory approval for treating EGFR mutant non-small cell lung cancer by 2029 in the U.S. and 2030 in the EU. With additional assets like ARR-217 targeting solid tumors, ArriVent's diversified therapeutic pipeline enhances its growth prospects, justifying BTIG's Buy rating and $29 price target.

Explore more price target data and ratings for ArriVent BioPharma on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [AVBP.US](https://longbridge.com/en/quote/AVBP.US.md)

## Related News & Research

- [ArriVent doses first patient in Phase 1 trial of ARR-002 dual-target ADC for ovarian, endometrial cancer](https://longbridge.com/en/news/301620875.md)
- [ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low](https://longbridge.com/en/news/301066580.md)
- [ArriVent says Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC misses primary PFS endpoint](https://longbridge.com/en/news/301032671.md)
- [ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)](https://longbridge.com/en/news/301079950.md)
- [TSMC Q3 Earnings Preview: Can Profit Hit a Record High for a Sixth Straight Quarter? Wall Street's Highest Target Price Is $665](https://longbridge.com/en/news/301683133.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**